Literature DB >> 21630666

Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.

R Matthew Cross1, Jordany R Maignan, Tina S Mutka, Lisa Luong, Justin Sargent, Dennis E Kyle, Roman Manetsch.   

Abstract

Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC(50) < 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630666     DOI: 10.1021/jm200015a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  4(1H)-Quinolones with liver stage activity against Plasmodium berghei.

Authors:  Alexis N Lacrue; Fabián E Sáenz; R Matthew Cross; Kenneth O Udenze; Andrii Monastyrskyi; Steven Stein; Tina S Mutka; Roman Manetsch; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

2.  4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities.

Authors:  Andrii Monastyrskyi; Dennis E Kyle; Roman Manetsch
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.

Authors:  Yiqun Zhang; Julie A Clark; Michele C Connelly; Fangyi Zhu; Jaeki Min; W Armand Guiguemde; Anupam Pradhan; Lalitha Iyer; Anna Furimsky; Jason Gow; Toufan Parman; Farah El Mazouni; Margaret A Phillips; Dennis E Kyle; Jon Mirsalis; R Kiplin Guy
Journal:  J Med Chem       Date:  2012-04-18       Impact factor: 7.446

4.  Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.

Authors:  Jennifer L Guler; John White; Margaret A Phillips; Pradipsinh K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

5.  Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.

Authors:  Raghupathi Neelarapu; Jordany R Maignan; Cynthia L Lichorowic; Andrii Monastyrskyi; Tina S Mutka; Alexis N LaCrue; Lynn D Blake; Debora Casandra; Sherwin Mashkouri; Jeremy N Burrows; Paul A Willis; Dennis E Kyle; Roman Manetsch
Journal:  J Med Chem       Date:  2018-02-09       Impact factor: 7.446

6.  4-(1H)-Quinolones and 1,2,3,4-Tetrahydroacridin-9(10H)-ones prevent the transmission of Plasmodium falciparum to Anopheles freeborni.

Authors:  Fabián E Sáenz; Alexis N Lacrue; R Matthew Cross; Jordany R Maignan; Kenneth O Udenze; Roman Manetsch; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

7.  Quinolone-3-diarylethers: a new class of antimalarial drug.

Authors:  Aaron Nilsen; Alexis N LaCrue; Karen L White; Isaac P Forquer; Richard M Cross; Jutta Marfurt; Michael W Mather; Michael J Delves; David M Shackleford; Fabian E Saenz; Joanne M Morrisey; Jessica Steuten; Tina Mutka; Yuexin Li; Grennady Wirjanata; Eileen Ryan; Sandra Duffy; Jane Xu Kelly; Boni F Sebayang; Anne-Marie Zeeman; Rintis Noviyanti; Robert E Sinden; Clemens H M Kocken; Ric N Price; Vicky M Avery; Iñigo Angulo-Barturen; María Belén Jiménez-Díaz; Santiago Ferrer; Esperanza Herreros; Laura M Sanz; Francisco-Javier Gamo; Ian Bathurst; Jeremy N Burrows; Peter Siegl; R Kiplin Guy; Rolf W Winter; Akhil B Vaidya; Susan A Charman; Dennis E Kyle; Roman Manetsch; Michael K Riscoe
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

8.  Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.

Authors:  Nicholas Fisher; Roslaini Abd Majid; Thomas Antoine; Mohammed Al-Helal; Ashley J Warman; David J Johnson; Alexandre S Lawrenson; Hilary Ranson; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Biol Chem       Date:  2012-01-26       Impact factor: 5.157

9.  Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1H)-Quinolones with Single Dose Cures.

Authors:  Andrii Monastyrskyi; Fabian Brockmeyer; Alexis N LaCrue; Yingzhao Zhao; Steven P Maher; Jordany R Maignan; Vivian Padin-Irizarry; Yana I Sakhno; Prakash T Parvatkar; Ami H Asakawa; Lili Huang; Debora Casandra; Sherwin Mashkouri; Dennis E Kyle; Roman Manetsch
Journal:  J Med Chem       Date:  2021-05-12       Impact factor: 8.039

10.  ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.

Authors:  Jordany R Maignan; Cynthia L Lichorowic; James Giarrusso; Lynn D Blake; Debora Casandra; Tina S Mutka; Alexis N LaCrue; Jeremy N Burrows; Paul A Willis; Dennis E Kyle; Roman Manetsch
Journal:  J Med Chem       Date:  2016-07-12       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.